AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy
AC099850.3 accelerates the cell cycle progression and promotes the occurrence and development of HBV-HCC by upregulating immune checkpoint CD276 expression. CC@AC&SF@PP NPs loaded with AC099850.3 siRNA and SF improve the effectiveness of combined therapy for HBV-HCC.
Authors
- Qian Feng (ORCID: https://orcid.org/0000-0002-1967-3796)
- Aoxiao He (ORCID: https://orcid.org/0000-0003-1932-4411)
- Jiakun Wang (ORCID: https://orcid.org/0000-0002-7594-014X)
- Zhihao Huang (ORCID: https://orcid.org/0000-0003-2638-8237)
- Shan Zhang (ORCID: https://orcid.org/0009-0009-4050-4063)
- Fan Li (ORCID: https://orcid.org/0009-0009-6274-6100)
- Hongcheng Lu (ORCID: https://orcid.org/0009-0005-6350-231X)
- Dan Li (ORCID: https://orcid.org/0000-0002-5262-382X)
Institutions
- Nanchang University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1186/s12967-024-05576-y
- Citations
- 3
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Nanchang University